Patient Rating:

4.7 out of 5

56 Patient Ratings
30 Patient Comments

Mary Elizabeth Hartnett, M.D.

Specialties

Languages

  • English

Clinical Details

Schedule An Appointment Clinical Office Address
(801) 581-2352 John A. Moran Eye Center
65 N Mario Capecchi
Salt Lake City, UT 84132
Map

Bio

M.E. Hartnett is a vitreoretinal surgeon, who treats and manages adult and pediatric retinal cases. Dr. Hartnett's clinical interests include vitreoretinal surgical diseases, including retinopathy of prematurity, or abnormal blood vessel development in the eye of a premature baby; pediatric vitreoretinopathies; trauma; retinal detachments; and diabetic eye disease. She also has a special interest in age-related macular degeneration.

Dr. Hartnett joined the Moran Eye Center in 2010 and will be building a pediatric retina center and a pediatric and adult retina clinical practice here. She performs surgery at both the Moran Eye Center and the Moran Pediatric Clinic at Primary Children's Medical Center.

Board Certification and Academic Information

Academic Departments Ophthalmology/Visual Sciences - Professor
Neurobiology and Anatomy - Adjunct Professor
Pediatrics - Adjunct Professor
Academic Divisions Pediatric Administration
Board Certification American Board of Ophthalmology

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.

Responses are measured on a scale of 1 to 5 with 5 being the best score.

Likelihood of recommending care provider
4.9
My confidence in care provider
4.9
Time care provider spent with me
4.7
Care provider spoke using clear language
4.8
Care provider's effort to include me in decisions
4.7
Care provider's concern for questions & worries
4.7
Care provider's explanation of condition/problem
4.6
Wait time at clinic
3.7
Care provider's friendliness and courtesy
4.8

Patient Comments

Patient comments are gathered from our Press Ganey Patient Satisfaction Survey and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.

June 08, 2014

the MD was fine. The wait time is too long for me to recommend this facility to others for eye care.

May 25, 2014

I was very impressed with doctors I saw, made a frightening experience not bad at all.

May 25, 2014

Moran Eye Center is a great service to have so close by.

May 19, 2014

Dr Hartnet is AMAZING!!!!

April 28, 2014

GOOD EXPERIENCE

March 30, 2014

Could have been better if physician and fellow examined at same time so I wouldn't have to have discomfort of lights twice.

March 17, 2014

Doctor Hartnet is very professional and caring with patients--she includes me in decisions--I credit her with saving my sight in my right eye---she is an excellent physican----

February 12, 2014

The care that I receive from Dr Hartnett is very good and she explains things well. However the assistant that dilated my eyes when they should not have been was not good at all.

December 22, 2013

Dr. Hartnet was always very caring, engaged and helpful. A couple of her assistants/fellows (?) were less so and maybe even a little rough during exam of retinal tear (however, that may have been absolutely necessary. Dr. Hartnet was more gentle in her approach).

November 28, 2013

I am usually seen by Dr. Hobbs and then by Dr. Hartnett. Both are very professional, and have done a wonderful job with my complicated case.

November 18, 2013

Excellent.

November 18, 2013

We would recommend Dr. Hartnett but the wait time was excessive. Also we were sent out to the reception waiting room and then called back into an exam room to schedule a procedure. We had to wait again for the person scheduling the procedure. It just seemed like the flow of how things ran there needed some work.

November 11, 2013

Dr. B was awesome. He was straight forward explaining the situation to me abt what was happening and might happen with my retina. Too bad he couldn't/didn't need to stay longer and visit. I like him.

October 21, 2013

I never saw the physician, just her fellow.

October 14, 2013

I am always thankful for specialists. They have worked hard for their knowledge.

October 07, 2013

Dr. Hartnett is clearly a consummate professional who is willing to explain and discuss my condition and the possible need for further treatment.

October 07, 2013

Dr. Hartnett has been fantastic. She has done everything possible to deal with my difficult case with the best possible outcome.

September 09, 2013

We drive 4 hours in order to see Dr. Lenahan, she is incredible to work with. I wouldn't want to see another provider even if they were "in-network"!

September 09, 2013

I have a problem with hearing when I can't see. Another thing I have a problem with is that by the time they actual DR comes in I am so dilated that I can't see the Dr.'s face. I don't know what she looks like.

September 02, 2013

okay. Primary Doctors time with us was limited

August 08, 2013

Good

July 15, 2013

I think there is a disconnect between me and the care provider. The care provider seems to be focusing her attention on my good eye where I really am still concerned with my bad eye. I could really use some help in knowing what I can do to minimize the symptoms or resolve the problem. I feel lost. I cannot describe the difficulties i've had in trying to cope with this and yet I feel like i'm left on my own to try and figure it out.

June 05, 2013

I was unable to see the doctor - my contact lenses were out. But he was terrific. Very competent and patient.

June 04, 2013

thanks to dr harnet my son can see!!!!!!!!!!!!!!

April 01, 2013

everything was excellent except for the LONG wait.

February 26, 2013

I am extremely impressed with the way doctor hartnett, and shokor(spelled wrong) diagnosed my problem. I've never been shown that kind and that much attention to any of my problems ever. Dr. Hartnett even came back after emergency surgery to make sure I was seen and looked at. I really felt like they cared and they wanted to make sure I was diagnosed correctly. My problem I know is a difficult one to diagnose, but I know they will find out what the problem is and help me. I would highly recommend others to go to the Moran eye center.

February 18, 2013

Dr. Hartnet and the other doctor were very nice and thorough

November 12, 2012

dr hartnet is the best pediatric retna specialist. she has a great bedside manner

November 06, 2012

I have a serious retinal condition and these guys/gals knew what they were doing/talking about. Excellent facility.

November 05, 2012

Dr. Hartnett pays such close attention my description of symptoms, and my physical exam is so meticulous. Her analysis of the situation is transparent which I appreciate.

Academic Profile

Board Certification and Academic Information

Academic Departments Ophthalmology/Visual Sciences - Professor
Neurobiology and Anatomy - Adjunct Professor
Pediatrics - Adjunct Professor
Academic Divisions Pediatric Administration
Board Certification American Board of Ophthalmology

Academic Office Locations

Academic Office Phone Number Academic Office Address
John A. Moran Eye Center
Moran Eye Center
65 N Mario Capecchi
Salt Lake City, UT 84132

Academic Bio

Mary Elizabeth Hartnett is a Doctor of Ophthalmology with a practice at the John A. Moran Eye Center at the University of Utah. She is a Professor at the University of Utah Department of Ophthalmology and Visual Sciences and an Adjunct Professor at the University of Utah Departments of Neurobiology and Anatomy and Department of Pediatrics. Dr. Hartnett is a vitreoretinal surgeon, who treats and manages adult and pediatric retinal cases. Dr. Hartnett's clinical interests include vitreoretinal surgical diseases, including retinopathy of prematurity, or abnormal blood vessel development in the eye of a premature baby; pediatric vitreoretinopathies; trauma; retinal detachments; and diabetic eye disease. She also has a special interest in age-related macular degeneration.

She received her undergraduate degree at Rensselaer Polytechnic Institute in Biology in the combined BS/MD program. She received her medical degree from Albany Medical College in the combined BS/MD program. Dr. Hartnett fulfilled post graduate training at Children’s Hospital and Schepens Eye Research Institute, Harvard University in molecular and cell biology and interned at University Hospitals of Cleveland. She completed a residency at University Hospitals of Cleveland, VA Medical Center in ophthalmology. She was awarded fellowships at Schepens Retina Associates and Massachusetts Eye and Ear Infirmary, Harvard Medical School, Schepens Retina Associates in vitreoretinal medical/surgical training in adult retina. Dr. Hartnett also worked as a research fellow at Schepens Eye Research Institute, Harvard Medical School and at Harvard University as Senior research ophthalmology fellow. Other training includes St. Peter's Hospital in hospice team training.

Dr. Hartnett joined the Moran Eye Center in 2010 and will be building a pediatric retina center and a pediatric and adult retina clinical practice here. She performs surgery at both the Moran Eye Center and the Moran Pediatric Clinic at Primary Children's Medical Center.

Education

Education History

Type School Degree
Post Graduate Training Children’s Hospital and Schepens Eye Research Institute, Harvard University
Molecular and Cell Biology
Postgraduate Studies
Fellowship Schepens Retina Associates, Massachusetts Eye and Ear Infirmary, Harvard Medical School
Vitreoretinal Medical/Surgical Training in Pediatric Retina
Fellow
Research Fellow Harvard University
Senior Research Ophthalmology Fellow
Research Fellow
Fellowship Schepens Retina Associates
Chief Fellow
Fellowship Massachusetts Eye and Ear Infirmary, Harvard Medical School, Schepens Retina Associates
Vitreoretinal Medical/Surgical Training in Adult Retina
Fellow
Research Fellow Schepens Eye Research Institute, Harvard Medical School
Research Fellow
Residency University Hospitals of Cleveland, VA Medical Center
Ophthalmology
Resident
Internship University Hospitals of Cleveland
Intern
Professional Medical Albany Medical College
Medicine (Combined BS/MD program)
M.D.
Undergraduate Rensselaer Polytechnic Institute
Biology (Combined BS/MD program)
B.S.
Other Training St. Peter's Hospital
Hospice Team Training

Publications

Selected Provider Publications

Journal Article

  1. Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations.Sleath B, Blalock SJ, Robin A, Hartnett ME, Covert D, DeVellis B, Giangiacomo A (2010). Development of an instrument to measure glaucoma medication self-efficacy and outcome expectations. Eye (Lond), 24(4), 624-31.
  2. New-Onset Maternal Gestational Hypertension and Risk of Retinopathy of Prematurity.Zayed M, Uppal A, Hartnett ME (2010). New-Onset Maternal Gestational Hypertension and Risk of Retinopathy of Prematurity. Invest Ophthalmol Vis Sci.
  3. Budd SJ, Hartnett ME (2010). Increased Angiogenic Compounds during Persistent Avascular Retina in a Model of ROP. Arch Ophthalmol, 128(8), 1014-21.
  4. SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion.Scott IU, VanVeldhuisen PC, Oden NL, Ip MS, Blodi BA, Jumper JM, Figueroa M and the SCORE Study Investigator Group (2009). SCORE Study report 1: baseline associations between central retinal thickness and visual acuity in patients with retinal vein occlusion. Ophthalmology, 116(3), 504-12.
  5. Chloride intracellular channel protein-4 functions in angiogenesis by supporting acidification of vacuoles along the intracellular tubulogenic pathway.Ulmasov B, Bruno J, Gordon N, Hartnett ME, Edwards JC (2009). Chloride intracellular channel protein-4 functions in angiogenesis by supporting acidification of vacuoles along the intracellular tubulogenic pathway. Am J Pathol, 174(3), 1084-96.
  6. Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings.Brucker AJ, Qin H, Antoszyk AN, Beck RW, Bressler NM, Browning DJ, Elman MJ, Glassman AR, Gross JG, Kollman C, Wells JA 3rd (2009). Observational study of the development of diabetic macular edema following panretinal (scatter) photocoagulation given in 1 or 4 sittings. Arch Ophthalmol, 127(2), 132-40.
  7. The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model.Byfield G, Budd S, Hartnett ME (2009). The role of supplemental oxygen and JAK/STAT signaling in intravitreous neovascularization in a ROP rat model. Invest Ophthalmol Vis Sci, 50(7), 3360-5.
  8. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema.Diabetic Retinopathy Clinical Research Network DRCRnet, Beck RW, Edwards AR, Aiello LP, Bressler NM, Ferris F, Glassman AR, Hartnett E, Ip MS, Kim JE, Kollman C (2009). Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol, 127(3), 245-51.
  9. SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type.Scott IU, Blodi BA, Ip MS, Vanveldhuisen PC, Oden NL, Chan CK, Gonzalez V and the SCORE Study Investigator Group (2009). SCORE Study Report 2: Interobserver agreement between investigator and reading center classification of retinal vein occlusion type. Ophthalmology, 116(4), 756-61.
  10. CCR3 is a target for age-related macular degeneration diagnosis and therapy.Takeda A, Baffi JZ, Kleinman ME, Cho WG, Nozaki M, Yamada K, Kaneko H, Albuquerque RJ, Dridi S, Saito K, Raisler BJ, Budd SJ, Geisen P, Munitz A, Ambati BK, Green MG, Ishibashi T, Wright JD, Humbles AA, Gerard CJ, Ogura Y, Pan Y, Smith JR, Grisanti S, Hartnett ME, Rothenberg ME, Ambati J (2009). CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature, 460(7252), 225-30.
  11. Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP.Budd S, Byfield G, Martiniuk D, Geisen P, Hartnett ME (2009). Reduction in endothelial tip cell filopodia corresponds to reduced intravitreous but not intraretinal vascularization in a model of ROP. Exp Eye Res, 89(5), 718-27.
  12. Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus.Hartnett ME, Tinkham N, Paynter L, Geisen P, Rosenberg P, Koch G, Cohen KL (2009). Aqueous vascular endothelial growth factor as a predictor of macular thickening following cataract surgery in patients with diabetes mellitus. Am J Ophthalmol, 148(6), 895-901.e1.
  13. Reynolds R, Hartnett ME, Rosner B, Atkinson J, Giclas PC, Seddon JM (2009). Plasma Complement Components and Activation Fragments are Associated with Age-Related Macular Degeneration Genotypes and Phenotypes. Invest Ophthalmol Vis Sci.
  14. Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema.Scott IU, Bressler NM, Bressler SB, Browning DJ, Chan CK, Danis RP, Davis MD, Kollman C, Qin H and the and the Diabetic Retinopathy Clinical Research Network Study Group (2008). Agreement between clinician and reading center gradings of diabetic retinopathy severity level at baseline in a phase 2 study of intravitreal bevacizumab for diabetic macular edema. Retina, 28(1), 36-40.
  15. Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach.Vinekar A, Trese MT, Capone A Jr on behalf of PhotoROP group (2008). Evolution of retinal detachment in posterior retinopathy of prematurity: impact on treatment approach. Am J Ophthalmol, 145(3), 548-555.
  16. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy.Bressler NM, Edwards AR, Antoszyk AN, Beck RW, Browning DJ, Ciardella AP, Danis RP, Elman MJ, Friedman SM, Glassman AR, Gross JG, Li HK, Murtha TJ, Stone TW, Sun JK on behalf of the Diabetic Retinopathy Clinical Research Network (2008). Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol, 145(5), 894-901.
  17. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema.Davis MD, Bressler SB, Aiello LP, Bressler NM, Browning DJ, Flaxel CJ, Fong DS, Foster WJ, Glassman AR, Hartnett ME, Kollman C, Li HK, Qin H, Scott IU (2008). Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci, 49(5), 1745-52.
  18. Subretinal hemorrhage after lens-sparing vitrectomy in infants born at or under 24 weeks gestation.Hartnett ME, Board RJ, Houghton O (2008). Subretinal hemorrhage after lens-sparing vitrectomy in infants born at or under 24 weeks gestation. Retina, 28(3 Suppl), S69-74.
  19. Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity.Geisen P, Peterson LJ, Martiniuk D, Uppal A, Saito Y, Hartnett ME (2008). Neutralizing antibody to VEGF reduces intravitreous neovascularization and may not interfere with ongoing intraretinal vascularization in a rat model of retinopathy of prematurity. Mol Vis, 14, 345-57.
  20. Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease.Hartnett ME, Martiniuk D, Byfield G, Geisen P, Zeng G, Bautch VL (2008). Neutralizing VEGF decreases tortuosity and alters endothelial cell division orientation in arterioles and veins in a rat model of ROP: relevance to plus disease. Invest Ophthalmol Vis Sci, 49(7), 3107-14.
  21. Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model.Saito Y, Uppal A, Byfield G, Budd S, Hartnett ME (2008). Activated NAD(P)H oxidase from supplemental oxygen induces neovascularization independent of VEGF in retinopathy of prematurity model. Invest Ophthalmol Vis Sci, 49(4), 1591-8.
  22. Vascular endothelial growth factor in eye disease.Penn JS, Madan A, Caldwell RB, Bartoli M, Caldwell RW, Hartnett ME (2008). Vascular endothelial growth factor in eye disease. Prog Retin Eye Res, 27(4), 331-71.
  23. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema.Browning DJ, Glassman AR, Aiello LP, Bressler NM, Bressler SB, Danis RP, Davis MD, Ferris FL, Huang SS, Kaiser PK, Kollman C, Sadda S, Scott IU, Qin H for DRCRnet (2008). Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology, 115(8), 1366-71, 1371.e1.
  24. A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features.Ip MS, Bressler SB, Antoszyk AN, Flaxel CJ, Kim JE, Friedman SM, Qin H for Health Research and the Diabetic Retinopathy Clinical Research Network (2008). A randomized trial comparing intravitreal triamcinolone and focal/grid photocoagulation for diabetic macular edema: baseline features. Retina, 28(7), 919-30.
  25. Diabetic Retinopathy Clinical Research Network (2008). A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology, 115, 1445-1456.
  26. Jacobson MA, Tan QX, Girling V, Poon C, Van Natta M, Jabs DA, Inokuma M, Maecker HT, Bredt B, and Sinclair E, for the Studies of Ocular Complications of AIDS Research Group (2008). Poor predictive value of cytomegalovirus (CMV)-Specific T cell assays for the development of CMV retinitis in patients with AIDS. Clin Infect Dis, 46, 458-466.
  27. Writing Committee for The Photographic Screening for Retinopathy of Prematurity Study Photo- ROP (2008). Primary Outcomes Ophthalmology. Retina, 28, S47-S54.
  28. Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. [This was a plenary paper with a commentary]Zeng G, Taylor SM, McColm JR, Kappas NC, Kearney JB, Williams LH, Hartnett ME, Bautch VL (2007). Orientation of endothelial cell division is regulated by VEGF signaling during blood vessel formation. [This was a plenary paper with a commentary]. Blood, 109(4), 1345-52.
  29. Heterotypic RPE-choroidal endothelial cell contact increases choroidal endothelial cell transmigration via PI 3-kinase and Rac1.Peterson LJ, Wittchen ES, Geisen P, Burridge K, Hartnett ME (2007). Heterotypic RPE-choroidal endothelial cell contact increases choroidal endothelial cell transmigration via PI 3-kinase and Rac1. Exp Eye Res, 84(4), 737-44.
  30. Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity.Saito Y, Geisen P, Uppal A, Hartnett ME (2007). Inhibition of NAD(P)H oxidase reduces apoptosis and avascular retina in an animal model of retinopathy of prematurity. Mol Vis, 13, 840-53.
  31. The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials.Bhavsar AR, Ip MS, Glassman AR, DRCRnet and the SCORE Study Groups (2007). The risk of endophthalmitis following intravitreal triamcinolone injection in the DRCRnet and SCORE clinical trials. Am J Ophthalmol, 144(3), 454-6.
  32. CIB1 regulates endothelial cells and ischemia-induced pathological and adaptive angiogenesis.Zayed MA, Yuan W, Leisner TM, Chalothorn D, McFadden AW, Schaller MD, Hartnett ME, Faber JE, Parise LV (2007). CIB1 regulates endothelial cells and ischemia-induced pathological and adaptive angiogenesis. Circ Res, 101(11), 1185-93.
  33. Steering Committee of Diabetic Retinopathy Clinical Research Network (2007). A phase 2 randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology, 114, 1860-1867.
  34. Diabetic Retinopathy Clinical Research Network (2007). Comparison of the modified early treatment diabetic retinopathy study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol, 125(4), 469-80.
  35. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, for the Studies of Ocular Complications of AIDS Research Group (2007). Longitudinal Study of the Ocular Complications of AIDS. 1. Ocular diagnoses at enrollment. Ophthalmology, 114, 780-786.
  36. Jabs DA, Van Natta ML, Holbrook JT, Kempen JH, Meinert CL, Davis MD, for the Studies of Ocular Complications of AIDS Research Group (2007). Longitudinal Study of the Ocular Complications of AIDS. 2. Ocular examination results at enrollment. Ophthalmology, 114, 787-793.
  37. Diabetic Retinopathy Clinical Research Network (2007). Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology, 114(3), 525-36.
  38. Diabetic Retinopathy Clinical Research Network (2007). Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology, 114(8), 1520-5.
  39. Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor.Geisen P, McColm JR, Hartnett ME (2006). Choroidal endothelial cells transmigrate across the retinal pigment epithelium but do not proliferate in response to soluble vascular endothelial growth factor. Exp Eye Res, 82(4), 608-19.
  40. Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis.McColm JR, Geisen P, Peterson LJ, Hartnett ME (2006). Exogenous leukemia inhibitory factor (LIF) attenuates retinal vascularization reducing cell proliferation not apoptosis. Exp Eye Res, 83(2), 438-46.
  41. Quantification of macular and optic disc hyperfluorescence after phacoemulsification in diabetes mellitus.Escaravage GK Jr, Cohen KL, Patel SB, Hartnett ME, Armstrong BD, Janowski CM (2006). Quantification of macular and optic disc hyperfluorescence after phacoemulsification in diabetes mellitus. J Cataract Refract Surg, 32(5), 803-11.
  42. Fibrovascular organization in the vitreous following laser for ROP: implications for prognosis.Hartnett ME, McColm JR (2006). Fibrovascular organization in the vitreous following laser for ROP: implications for prognosis. Retina, 26(7 Suppl), S24-31.
  43. The Photographic Screening for Retinopathy of Prematurity Study (Photo-ROP): study design and baseline characteristics of enrolled patients.Balasubramanian M, Capone A Jr, Hartnett ME, Pignatto S, Trese MT (2006). The Photographic Screening for Retinopathy of Prematurity Study (Photo-ROP): study design and baseline characteristics of enrolled patients. Retina, 26(7 Suppl), S4-10.
  44. Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture.Geisen P, McColm JR, King BM, Hartnett ME (2006). Characterization of barrier properties and inducible VEGF expression of several types of retinal pigment epithelium in medium-term culture. Curr Eye Res, 31(9), 739-48.
  45. Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy.Hartnett ME, Martiniuk DJ, Saito Y, Geisen P, Peterson LJ, McColm JR (2006). Triamcinolone reduces neovascularization, capillary density and IGF-1 receptor phosphorylation in a model of oxygen-induced retinopathy. Invest Ophthalmol Vis Sci, 47(11), 4975-82.
  46. Thorne JE, Jabs DA, Kempen JH, Holbrook JT, Nichols C, Meinert CL, for the Studies of Ocular Complications of AIDS Research Group (2006). Causes of Visual Acuity Loss Among Patients with AIDS and Cytomegalovirus in the Era of Highly Active Antiretroviral Therapy. Ophthalmology, 113, 1441-1445.
  47. Diabetic Retinopathy Clinical Research Network (2006). Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol, 124(12), 1701-7.
  48. PKC-DRS2 Group PI for LSU site (2006). Effect of Ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology, 113, 2221-2230.
  49. Kempen JH, Min Y-I, Freeman WR, Holland GN, Friedberg DN, Dieterich DT, Jabs DA for the Studies of Ocular Complications of AIDS Research Group (2006). Risk of immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis. Ophthalmology, 113, 684-694.
  50. Perceived barriers to diabetic eye care: qualitative study of patients and physicians.Hartnett ME, Key IJ, Loyacano NM, Horswell RL, Desalvo KB (2005). Perceived barriers to diabetic eye care: qualitative study of patients and physicians. Arch Ophthalmol, 123(3), 387-91.
  51. Retinal features predictive of progressive stage 4 retinopathy of prematurity.Hartnett ME, McColm JR (2004). Retinal features predictive of progressive stage 4 retinopathy of prematurity. Retina, 24(2), 237-41.
  52. Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis.Van Cott EM, Laposata M, Hartnett ME (2004). Prothrombin gene mutation G20210A, homocysteine, antiphospholipid antibodies and other hypercoagulable states in ocular thrombosis. Blood Coagul Fibrinolysis, 15(5), 393-7.
  53. VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP.McColm JR, Geisen P, Hartnett ME (2004). VEGF isoforms and their expression after a single episode of hypoxia or repeated fluctuations between hyperoxia and hypoxia: relevance to clinical ROP. Mol Vis, 10, 512-20.
  54. Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity.Hartnett ME, Maguluri S, Thompson HW, McColm JR (2004). Comparison of retinal outcomes after scleral buckle or lens-sparing vitrectomy for stage 4 retinopathy of prematurity. Retina, 24(5), 753-7.
  55. Marshall BC, Jacobson MA, Adler SP in collaboration with the Studies of Ocular Complications of AIDS Research Group (2004). Avidity of antibodies to cytomegalovirus in HIV-seropositive patients with and without CMV retinitis. Viral Immunol, 17, 101-108.
  56. Jabs DA, Van Natta ML, Thorne JE, Weinberg DV, Meredith TA, Kuppermann BD, Sepkowitz K, Li HK for the Studies of Ocular Complications of AIDS Research Group (2004). Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology, 111, 2232-2239.
  57. Jacobson MA, Maecker HT, Orr PL, DAmico R, Van Natta M, Li XD Pollard RB, Bredt BM for the Adult AIDS Clinical Trials Groupand the Studies of Ocular Complications of AIDS Research Group (2004). Results of a CMV-specific CD8+/IFNy+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in AIDS patients with CMV retinitis. J Infect Dis, 189, 1362-1373.
  58. Antiphospholipid antibody syndrome in a six-year-old female patient.Hartnett ME, Laposata M, Van Cott E (2003). Antiphospholipid antibody syndrome in a six-year-old female patient. Am J Ophthalmol, 135(4), 542-4.
  59. Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity.Hartnett ME (2003). Features associated with surgical outcome in patients with stages 4 and 5 retinopathy of prematurity. Retina, 23(3), 322-9.
  60. Long-term vision results measured with Teller Acuity Cards and a new Light Perception/Projection Scale after management of late stages of retinopathy of prematurity.Hartnett ME, Rodier DW, McColm JR, Thompson HW (2003). Long-term vision results measured with Teller Acuity Cards and a new Light Perception/Projection Scale after management of late stages of retinopathy of prematurity. Arch Ophthalmol, 121(7), 991-6.
  61. Radial choroidal ruptures in sclopetaria.Maguluri S, Hartnett ME (2003). Radial choroidal ruptures in sclopetaria. J Am Coll Surg, 197(4), 689-90.
  62. Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism.Hartnett ME, Lappas A, Darland D, McColm JR, Lovejoy S, DAmore PA (2003). Retinal pigment epithelium and endothelial cell interaction causes retinal pigment epithelial barrier dysfunction via a soluble VEGF-dependent mechanism. Exp Eye Res, 77(5), 593-9.
  63. Kempen JH, Martin BK, Wu A, Barron B, Thorne JE, Jabs DA for the Studies of Ocular Complications of AIDS Research Group (2003). The effect of cytomegalovirus retinitis on the quality of life of patients with acquired immune deficiency syndrome in the era of highly active anti-retroviral therapy. Ophthalmology, 110, 987-995.
  64. Holbrook JT, Jabs DA, Weinberg DV, Lewis RA, Davis MD, Friedberg D for the Studies of Ocular Complications of AIDS Research Group (2003). Visual loss in patients with cytomegalovirus retinitis and AIDS before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol, 121(1), 99-107.
  65. Grading of infrared confocal scanning laser tomography and video displays of digitized color slides in exudative age-related macular degeneration.Miura M, Elsner AE, Beausencourt E, Kunze C, Hartnett ME, Lashkari K, Trempe CL (2002). Grading of infrared confocal scanning laser tomography and video displays of digitized color slides in exudative age-related macular degeneration. Retina, 22(3), 300-8.
  66. Infrared scanning laser tomography of macular cysts.Beausencourt E, Remky A, Elsner AE, Hartnett ME, Trempe CL (2000). Infrared scanning laser tomography of macular cysts. Ophthalmology, 107(2), 375-85.
  67. Serum markers of oxidative stress and severity of diabetic retinopathy.Hartnett ME, Stratton RD, Browne RW, Rosner BA, Lanham RJ, Armstrong D (2000). Serum markers of oxidative stress and severity of diabetic retinopathy. Diabetes Care, 23(2), 234-40.
  68. The STOP-ROP Multicenter Study Group (2000). Supplemental Therapeutic Oxygen for Prethreshold Retinopathy of Prematurity (STOP-ROP), A randomized, controlled trial. I: Primary Outcomes. Pediatrics, 105, 295-310.
  69. Ophthalmic endoscopy: applications in intraocular surgery.Sheindlin JA, Hirose T, Hartnett ME (1999). Ophthalmic endoscopy: applications in intraocular surgery. Int Ophthalmol Clin, 39(1), 237-47.
  70. Surgical advances in retinopathy of prematurity.Andrews AP, Hartnett ME, Hirose T (1999). Surgical advances in retinopathy of prematurity. Int Ophthalmol Clin, 39(1), 275-90.
  71. Spatial extent of pigment epithelial detachments in age-related macular degeneration.Kunze C, Elsner AE, Beausencourt E, Moraes L, Hartnett ME, Trempe CL (1999). Spatial extent of pigment epithelial detachments in age-related macular degeneration. Ophthalmology, 106(9), 1830-40.
  72. Infrared imaging of cystoid macular edema.Remky A, Beausencourt E, Hartnett ME, Trempe CL, Arend O, Elsner AE (1999). Infrared imaging of cystoid macular edema. Graefes Arch Clin Exp Ophthalmol, 237(11), 897-901.
  73. Release of bFGF, an endothelial cell survival factor, by osmotic shock.Hartnett ME, Garcia CM, DAmore PA (1999). Release of bFGF, an endothelial cell survival factor, by osmotic shock. Invest Ophthalmol Vis Sci, 40(12), 2945-51.
  74. Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor.Armstrong D, Ueda T, Ueda T, Aljada A, Browne R, Fukuda S, Spengler R, Chou R, Hartnett M, Buch P, Dandona P, Sasisekharan R, Dorey CK (1998). Lipid hydroperoxide stimulates retinal neovascularization in rabbit retina through expression of tumor necrosis factor-alpha, vascular endothelial growth factor and platelet-derived growth factor. Angiogenesis, 2(1), 93-104.
  75. Cyanoacrylate glue in the repair of retinal detachment associated with posterior retinal breaks in infants and children.Hartnett ME, Hirose T (1998). Cyanoacrylate glue in the repair of retinal detachment associated with posterior retinal breaks in infants and children. Retina, 18(2), 125-9.
  76. Quantitative analysis of macular holes with scanning laser tomography.Beausencourt E, Elsner AE, Hartnett ME, Trempe CL (1997). Quantitative analysis of macular holes with scanning laser tomography. Ophthalmology, 104(12), 2018-29.
  77. Armstrong D, Ueda To, Ueda Ta, Browne R, Al-Jada A, Spengler R, Chou R, Fukuda S, Buch P, Dandona P, Hartnett ME, Sasisekharan R, Dorey KC (1997). Expression of TNF-alpha and VEGF during retinal neovascularization is initiated by lipid hydroperoxide. Angiogenesis, 2, 174-84.
  78. Characteristics of exudative age-related macular degeneration determined in vivo with confocal and indirect infrared imaging.Hartnett ME, Elsner AE (1996). Characteristics of exudative age-related macular degeneration determined in vivo with confocal and indirect infrared imaging. Ophthalmology, 103(1), 58-71.
  79. Difficulties in excluding the diagnosis of retinoblastoma in cases of advanced Coats' disease: a clinicopathologic report.Steidl SM, Hirose T, Sang D, Hartnett ME (1996). Difficulties in excluding the diagnosis of retinoblastoma in cases of advanced Coats' disease: a clinicopathologic report. Ophthalmologica, 210(6), 336-40.
  80. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration.Hartnett ME, Weiter JJ, Staurenghi G, Elsner AE (1996). Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. Ophthalmology, 103(12), 2042-53.
  81. Open-sky vitrectomy for posterior segment reconstruction in eyes with severe trauma.Steidl S, Hirose T, Hartnett ME (1995). Open-sky vitrectomy for posterior segment reconstruction in eyes with severe trauma. Int Ophthalmol Clin, 35(1), 175-80.
  82. Improved visual function in retinopathy of prematurity after lowering high intraocular pressure.Hartnett ME, Katsumi O, Hirose T, Richardson TM, Walton DS (1994). Improved visual function in retinopathy of prematurity after lowering high intraocular pressure. Am J Ophthalmol, 117(1), 113-5.
  83. Antiphospholipid antibody syndrome associated with microscotomata.Hartnett ME, Pruett RC, DaSilva KC, Burkart PT (1994). Antiphospholipid antibody syndrome associated with microscotomata. Am J Ophthalmol, 118(3), 397-8.
  84. Glaucoma as a cause of poor vision in severe retinopathy of prematurity.Hartnett ME, Gilbert MM, Hirose T, Richardson TM, Katsumi O (1993). Glaucoma as a cause of poor vision in severe retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol, 231(8), 433-8.
  85. Lens clarity after vitrectomy in traumatic lens perforation and vitreous penetration.Hartnett ME, Coles WH (1993). Lens clarity after vitrectomy in traumatic lens perforation and vitreous penetration. Am J Ophthalmol, 116(2), 250-1.
  86. Intraocular pressure determination in infants with severe retinopathy of prematurity.Hartnett ME, Hirose T, Richardson TM, Garsd A, Gilbert MM, Krug J Jr (1992). Intraocular pressure determination in infants with severe retinopathy of prematurity. Graefes Arch Clin Exp Ophthalmol, 230(5), 406-10.
  87. Classification of retinal pigment epithelial detachments associated with drusen.Hartnett ME, Weiter JJ, Garsd A, Jalkh AE (1992). Classification of retinal pigment epithelial detachments associated with drusen. Graefes Arch Clin Exp Ophthalmol, 230(1), 11-9.
  88. Anterior segment evaluation of infants with retinopathy of prematurity.Hartnett ME, Gilbert MM, Richardson TM, Krug JH Jr, Hirose T (1990). Anterior segment evaluation of infants with retinopathy of prematurity. Ophthalmology, 97(1), 122-30.
  89. Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis.Lazarus HM, Hartnett ME, Reed MD, Murphy BF, Lass JH (1987). Comparison of the prophylactic effects of 2-deoxycytidine and prednisolone for high-dose intravenous cytarabine-induced keratitis. Am J Ophthalmol, 104(5), 476-80.
  90. Natural killer cells suppress human erythroid stem cell proliferation in vitro.Mangan KF, Hartnett ME, Matis SA, Winkelstein A, Abo T (1984). Natural killer cells suppress human erythroid stem cell proliferation in vitro. Blood, 63(2), 260-9.
  91. Divergence paralysis.Krohel GB, Tobin DR, Hartnett ME, Barrows NA (1982). Divergence paralysis. Am J Ophthalmol, 94(4), 506-10.

Edited Book

  1. Hartnett ME, ed-in-chief (Eds.) (2005). Pediatric Retina. Philadelphia, PA: Lippincott Williams & Wilkins.
  2. Steidl S, Hartnett ME (Eds.) (2003). Clinical Pathways in Vitreoretinal Disease. New York, NY: Thieme Publishers.
  3. Schepens CL, Hartnett ME, Hirose T (Eds.) (2000). Schepens’ Retinal Detachment and Allied Diseases. (2nd edition). Boston, MA: Butterworth-Heinemann.

Clinical Trials

Clinical Trials

Video & News